Anuh Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
ANUHPHR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.1 pts less than Nifty Microcap 250 and 2.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Anuh Pharma reported Q1 FY26 revenue of Rs. 186.5 crore, up 35% from Rs. 137.9 crore in Q1 FY25, driven by higher raw material consumption and stock-in-trade purchases. However, profit after tax fell to Rs. 8.3 crore from Rs. 9.5 crore a year ago (-12.7%), and EBITDA margin compressed sharply from 10.36% to 7.34%, hurt by cost pressures. Basic EPS stood at Rs. 1.66 vs Rs. 1.90 in Q1 FY25. The statutory auditor (Jayantilal Thakkar & Co.) issued an unqualified limited review report with no qualifications or concerns flagged. Separately, the board appointed Mr. Vinayak Shenoy as Chief Marketing Officer effective August 11, 2025.
Strong top-line growth is a positive, but the sharp drop in EBITDA margin and lower PAT signal margin pressure that may concern investors in the near term. Watch for whether margin recovery happens in coming quarters. The new CMO appointment signals a focus on global sales growth in APIs and intermediates.